First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, endpoint design, and...
Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without...
FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and...
Compass Pathways' Phase 3 six-month data and a first-ever psilocybin-PTSD veteran trial signal readiness — but the guideline infrastructure...
Eli Lilly acquires AtaiBeckley for $2.8B, but the FDA's final psychedelic trial guidance reveals an operational crisis Big Pharma...
Compass Pathways' 39% six-month response rate and the FDA's final psychedelics guidance arrive together. The field looks ready. Look...
A Bayesian PET re-analysis finds ketamine and ECT both upregulate 5-HT1B receptors, pointing to a shared biomarker that TRD...
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...
A JAMA Psychiatry meta-analysis of 26 RCTs confirms ketamine's acute antidepressant effect. Here's what 1,166 trial patients don't show...
New Cell data pinpoints intratelencephalic neurons in the anterior insula as the mechanistic key to aiTBS antidepressant effects—here's what...
